News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post navigation Previous: EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories Healthcare Medicaid News Benchmark Senior Living Selects Sunbound to Help Modernize Resident Billing and Payments Staff November 19, 2026 Healthcare Medicaid News Benchmark Senior Living Selects Sunbound to Help Modernize Resident Billing and Payments Staff November 19, 2026 Healthcare News Omega Healthcare Earns Voice of the Customer Elevate Honor Recognition from Everest Group in the Healthcare and Life Sciences Services Category Staff November 19, 2026